Company Overview
DaVita Inc. functions as a specialized provider of kidney dialysis services, catering specifically to patients suffering from chronic kidney failure within the United States. The company operates a network of kidney dialysis centers and delivers associated laboratory services through outpatient facilities, while also offering outpatient, hospital inpatient, and home-based hemodialysis treatments. This organization operates within the Healthcare sector, specifically classified under the Medical Care Facilities industry, a classification that reflects its critical role in delivering essential life-sustaining medical procedures to a vulnerable patient population. As of the latest reporting data, the company commands a market capitalization of $10.01B and generates annual revenue of $13.64B, supporting a workforce of 78,000 employees. The scale indicated by a market cap exceeding $10 billion combined with revenue surpassing $13 billion underscores DaVita's position as a significant, large-cap entity capable of sustaining extensive operational networks and a massive human capital requirement to deliver continuous care services.
Financial Health
DaVita Inc. reported a trailing twelve-month revenue of $13.64B, with a corresponding net income of $721.80M and an EBITDA of $2.75B. The substantial gap between the $13.64B in revenue and the $721.80M in net income reveals a cost structure where operating expenses, including labor and supplies, consume approximately 94.5% of total sales before interest and taxes are considered. The company generated free cash flow of $1.05B, a metric that indicates a robust capacity to fund capital expenditures, service debt obligations, or pursue strategic initiatives without relying heavily on external financing. Three distinct margin metrics provide insight into profitability at different stages of the value chain: the gross margin stands at 32.3%, indicating the efficiency of direct service delivery relative to revenue; the operating margin is 15.2%, reflecting the company's ability to cover operating overheads; and the profit margin is 5.5%, which represents the final percentage of revenue converted into net earnings after all expenses. On the balance sheet, DaVita holds $700.74M in cash against a total debt load of $12.87B, resulting in a debt-to-equity ratio of 1111.35, which characterizes the capital structure as highly leveraged rather than conservative. Despite the high leverage, the current ratio of 1.29 suggests that the company maintains sufficient current assets to cover its short-term liabilities, indicating a baseline level of short-term liquidity stability. Management effectiveness is further highlighted by a return on equity of 64.8% and a return on assets of 7.3%, metrics that demonstrate the company's ability to generate significant returns on the shareholders' equity despite its heavy reliance on borrowed capital.
Valuation Assessment
Valuation multiples for DaVita Inc. show a trailing P/E ratio of 15.75 compared to a forward P/E of 9.17. The notable difference between these two figures implies that the market expects a significant expansion in earnings growth in the coming periods, as the forward multiple is substantially lower than the historical average. The price-to-book ratio is listed at -15.77, a negative figure that typically arises in capital-intensive healthcare sectors with high accumulated depreciation and indicates that the market price is significantly below the accounting book value per share. Alternative valuation metrics such as the price-to-sales ratio of 0.73 and the EV/EBITDA of 8.72 suggest that the company is valued at a discount relative to its sales and earnings power when adjusted for enterprise value. The stock has traded within a 52-week range with a high of $159.42 and a low of $101.00; based on the provided data, the valuation metrics imply a current trading position that must be contextualized against this wide historical range, though specific current pricing is not explicitly defined in the source data. The beta value of 0.93 indicates that the stock's price volatility is slightly lower than the broader market, suggesting that DaVita tends to move in tandem with the general market but with a dampened reaction to market-wide fluctuations.
Growth & Income
The company has demonstrated expansion with a revenue growth of 9.9% year-over-year and earnings growth of 6.5% year-over-year. The fact that earnings growth is proceeding at a slower pace than revenue growth implies that the company is either facing margin compression, increasing operating costs, or investing heavily in capacity that has not yet fully translated into bottom-line earnings. Regarding income distribution, DaVita does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of a payout indicates that the company currently prioritizes retaining earnings to fund its substantial debt obligations and operational growth rather than distributing cash to shareholders. Consequently, the overall growth and income profile for DaVita is characterized by capital appreciation potential and reinvestment into the business model rather than passive income generation through dividends.